PRONIA
Research

Making a few drops of blood enough for diagnosing cancer

CANCER-ID – Innovation in Medicine

 

Blood-based biomarkers, such as circulating tumor cells, circulating free tumor DNA and other tumor cell derivatives like micro RNAs, are potential indicators for the development of a tumor. Derivation of these markers from blood – so called “liquid biopsy” – may offer an additional invaluable tool for modern cancer therapy: apart from being of high importance when normal biopsies of the tumor are not accessible, blood-based tests may allow a close follow-up of disease markers offering a means to monitor the efficacy of treatment and potentially improve the choice of treatment options – paving the way for personalized medicine for the disease.

CANCER-ID offers a new way to track cancer


CANCER-ID is a newly formed European consortium supported by Europe’s Innovative Medicines Initiative (IMI). The Public-Private-Partnership with currently 36 partners from 13 countries aims at the establishment of standard protocols for and clinical validation of blood-based biomarkers. It brings together experts from academic and clinical research, innovative Small-to-Medium sized Enterprises (SMEs), diagnostics companies and the pharmaceutical industry thus providing a unique setting for establishing clinical utility of liquid biopsies.


Start Date:            1st January 2015
Project Duration:   5 Years
Funding:                € 16.7 Mio

Keywords

  • blood-based biomarkers
  • cancer
  • tumor DNA and microRNA
  • liquid biopsy

Key messages

  • CANCER-ID establishes standard protocols for blood-based biomarkers.
  • Its experts push along the clinical utility of liquid biopsies.
  • CANCER-ID is paving the way for personalized medicine for different types of cancer.
  • It offers a new way to track cancer.

CANCER-ID Consortium

CANCER-ID consortium
Search
Top
Home
Menu

EU logo
imi Logo
efpia Logo

News Section

Download the latest version of the free software that has been developed by our... Read more

Social Media

LinkedIn Cancer-ID